Loading clinical trials...

SELF-BREATHE RCT for Chronic Breathlessness | Clinical Trials | Clareo Health

COMPLETEDNA

SELF-BREATHE RCT for Chronic Breathlessness

A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial

NCT04574050•King's College Hospital NHS Trust

View on ClinicalTrials.gov

Summary

A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults ≥ 18 years of age, with the ability to read and type in English
•Access to a computer, or tablet or smart phone, with internet access and the ability to email
•Chronic breathlessness (CB) defined as; breathlessness that persists (\>3months) despite optimal pharmacological treatment of the underlying disease including cancer, chronic obstructive pulmonary disease (COPD),asthma, interstitial lung disease (ILD), bronchiectasis, cystic fibrosis (CF) chronic heart failure (CHF), sickle cell disease, chronic renal/ liver failure or post COVID-19
•Chronic breathlessness at rest or on exertion; MRC dysponea score \>2
•Willing to engage with short-term self-guided internet-based breathlessness intervention (SELF-BREATHE)
•Able to provide informed consent

Exclusion Criteria

•Breathlessness of unknown cause
•A primary diagnosis of chronic hyperventilation syndrome
•Currently participating in a rehabilitation programme, e.g. pulmonary/cardiac rehabilitation

Locations (1)

King's College Hospital NHS Foundation TRUST

London, United Kingdom

Key Dates

Start Date

January 11, 2021

Primary Completion Date

January 11, 2022

Completion Date

January 30, 2022

Last Updated

March 19, 2024

Enrollment

ACTUAL participants

Conditions

CancerCOPDAsthmaBronchiectasis AdultInterstitial Lung DiseaseCystic FibrosisChronic Heart FailureSickle Cell DiseaseRenal FailureLiver FailurePost COVID-19Dyspnea

Interventions

SELF-BREATHE

OTHER

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SELF-BREATHE RCT for Chronic Breathlessness

Inclusion Criteria

Exclusion Criteria

Magnetic Resonance Imaging of the Lung: Oncological Applications

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)